BioNTech to Hold Second AI Day, Part of Innovation Series, on October 1, 2025

Posted on by

MAINZ, Germany, September 23, 2025 — BioNTech (Nasdaq: BNTX, “BioNTech”), in collaboration with its artificial intelligence (“AI”) subsidiary InstaDeep (“InstaDeep”), is set to conduct its second AI Day. This event, part of BioNTech’s “Innovation Series,” will take place on Wednesday, October 1, 2025, at 09:00 a.m. EDT (3:00 p.m. CEST) in London, United Kingdom. The session will feature an exploration of BioNTech’s AI capabilities and strategic approach, alongside a demonstration of AI’s implementation across BioNTech’s development pipeline and internal operations.

A live webcast of the event will be accessible via this .

Attendees will also have the option to access the event’s slides and a recording through the “Events & Presentations” page within the Investor Relations section of BioNTech’s website at . The recording will be made available shortly after the event concludes and will remain archived on BioNTech’s website for a period of one year.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) operates as a leading global next-generation immunotherapy firm, dedicated to pioneering innovative investigative treatments for cancer and other serious medical conditions. BioNTech leverages an extensive range of computational discovery and therapeutic approaches with the goal of rapidly advancing novel biopharmaceutical products. Its comprehensive portfolio of oncology product candidates is designed to address the entire spectrum of cancer, encompassing mRNA cancer immunotherapies, advanced immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and cutting-edge chimeric antigen receptor (CAR) T cell therapies. Drawing upon its profound expertise in mRNA development and proprietary manufacturing capabilities, BioNTech and its partners are actively engaged in researching and developing numerous mRNA vaccine candidates for various infectious diseases, in addition to its diverse oncology pipeline. BioNTech has cultivated a wide network of relationships with both global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (a member of the Roche Group), Genevant, Genmab, MediLink, OncoC4, Pfizer, and Regeneron.

For further details, please visit .

CONTACTS

Investor Relations
Douglas Maffei, PhD

Media Relations
Jasmina Alatovic